Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Validation of a New Immunochemistry Method Using Antibody of Methionyl-tRNA synthetase1(MARS1) in the Pancreatic Cancer Cell; Multicenter Prospective Study

NCT04293497 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT04293497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04293497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Validation of a New Immunochemistry Method Using Antibody of Methionyl-tRNA synthetase1(MARS1) in the Pancreatic Cancer Cell; Multicenter Prospective Study
Lead sponsor
Gangnam Severance Hospital
Phase
Not applicable
Overall status
Completed
Start date
February 17, 2020
Completion date
July 2, 2021
Enrollment
97 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer